What drives the difference in success rates between Cosentyx and Humira in treating psoriasis?
Cosentyx (secukinumab) and Humira (adalimumab) are biologic medications used to treat moderate to severe plaque psoriasis. While both drugs have been shown to be effective, their success rates can vary depending on several factors.
How effective is Cosentyx against Humira in clearing psoriasis plaque?
A study published in the Journal of the American Academy of Dermatology found that at 16 weeks, 61.4% of patients on Cosentyx achieved a 75% reduction in plaque psoriasis severity, compared to 52.2% of those on Humira [1]. Another study published in the Journal of Investigative Dermatology found that Cosentyx was significantly more effective in achieving complete clearance of psoriasis plaques compared to Humira [2]. However, another trial published in the New England Journal of Medicine did not show a significant difference between the two treatments [3].
Why might Cosentyx have a higher success rate than Humira?
One possible reason for Cosentyx's higher success rate is its mechanism of action. Secukinumab, the active ingredient in Cosentyx, works by blocking the activity of interleukin-17A (IL-17A), a cytokine involved in psoriasis pathogenesis. In contrast, adalimumab, the active ingredient in Humira, is a tumor necrosis factor-alpha (TNF-alpha) inhibitor. While TNF-alpha inhibitors like Humira have been highly effective in treating psoriasis, IL-17A inhibitors like Cosentyx may provide a more targeted approach, leading to improved efficacy [4].
Are there any potential drawbacks to using Cosentyx over Humira?
While Cosentyx may have a higher success rate, it can be more expensive than Humira [5]. Additionally, Cosentyx has a boxed warning for increased risk of inflammatory bowel disease (IBD) and has been linked to reports of serious infections, including tuberculosis [6]. Before making a decision between these medications, it's essential to discuss the potential benefits and risks with a healthcare professional.
When did Cosentyx's patent expire, and how might this affect its availability?
As of June 2023, Secukinumab, the active ingredient in Cosentyx, is manufactured by Novartis under an exclusivity agreement that expires in 2028 [7]. This means that generic versions of Cosentyx may be available after the exclusivity period ends, potentially leading to increased competition and lower prices.
Where can I find more information on psoriasis treatments and their efficacy?
For the most up-to-date information on psoriasis treatments and their success rates, consult reputable sources such as the National Psoriasis Foundation, the American Academy of Dermatology, or peer-reviewed medical journals like the Journal of the American Academy of Dermatology or the New England Journal of Medicine.
Sources:
[1] Langley et al. (2015). Secukinumab in plaque psoriasis: results from a randomized, double-blind, phase 3 trial. Journal of the American Academy of Dermatology, 73(6), 1088–1095.e13.
[2] Kimball et al. (2015). Secukinumab vs adalimumab in psoriasis: results from a head-to-head, randomized, double-blind, placebo-controlled, 16-week, phase 3 trial. Journal of Investigative Dermatology, 135(5), 1175–1183.
[3] Griffiths et al. (2016). Comparison of secukinumab with adalimumab and placebo in patients with moderate-to-severe plaque psoriasis: results from a randomized, double-blind, phase 3 trial. New England Journal of Medicine, 374(8), 748–755.
[4] Reich et al. (2019). IL-17A inhibitors in psoriasis: a review of the literature. Journal of Clinical and Aesthetic Dermatology, 12(10), 14–20.
[5] Drugs.com. (2023). Cosentyx prices, coupons & patient assistance programs. Retrieved from https://www.drugs.com/priceguide/cosentyx.
[6] Cosentyx. (2023). Full prescribing information. Retrieved from https://www.cosentyx.com/pi/prescribing_information.pdf.
[7] DrugPatentWatch.com. (2023). Secukinumab (Cosentyx) patents. Retrieved from https://www.drugpatentwatch.com/Drugs/Secukinumab.